Structure-Based Drug Design Summit on July 26-28, 2026 in Boston, United States

As drug discovery pipelines face tighter budgets and greater pressure to deliver confident decisions earlier, structure-based drug design is becoming a central driver of modern R and D strategy. Biopharma teams are increasingly combining high-resolution structural biology with AI-enabled modelling and computational design to tackle complex targets, prioritize compounds faster, and reduce risk across discovery programs.

While predictive technologies continue to advance, their true value lies in how effectively they integrate with experimental structural data. From cryo-EM breakthroughs and expanding structural resolution to the growing role of validated AI in modelling and construct design, the ability to connect computational prediction, structural insight and wet-lab validation is now critical for unlocking challenging targets and accelerating discovery.

The 3rd Structure-Based Drug Design Summit Boston returns as the go-to industry-dedicated forum focused exclusively on the practical application of structural biology and AI across early drug discovery workflows. Bringing together structural biologists, medicinal chemists, computational scientists and discovery leaders, the meeting showcases how leading organizations are applying cryo-EM, structural data and predictive modelling to guide target selection, optimize compounds and strengthen discovery decisions.

Through expert-led case studies, interactive discussions and collaborative networking, you’ll gain practical insight into solving complex targets across modalities from membrane proteins and GPCRs to induced-proximity therapeutics, biologics and next-generation modalities.

URLs:
Tickets: https://go.evvnt.com/3543663-2?pid=10008
Brochure: https://go.evvnt.com/3543663-3?pid=10008

Time: 8:00 AM - 5:00 PM

Venue Details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States

Category: Conferences | Science, Health and Medicine

Prices:

Drug Developer Price - Full Package – Conference + Workshop Day: USD 3597.00,

Drug Developer Price - Conference Only: USD 2699.00,

Academic Price - Full Package – Conference + Workshop Day: USD 2997.00,

Academic Price - Conference Only: USD 2299.00,

Service Provider Price - Full Package – Conference + Workshop Day: USD 5397.00,

Service Provider Price - Conference Only: USD 3899.00

Speakers: Vincent Stoll, Senior Director and Fellow in Research and Structural Biology, Abbvie, Frank Teets, Head of Computational Biology, AI Proteins, Ian Storer, Vice President of Hit Discovery and Open Innovation, AstraZeneca, Frank Von Delft, Head of Protein Crystallography, Centre for Medicines Discovery, Beatrice Li, Head of Protein Science and Structural Biology, Confo Therapeutics, Deirdre Costello, Associate Director, Structural Biology, Genesis Molecular AI, Lena Dolgikh, Head of Computational Chemistry, Monte Rosa Therapeutics, Breanna Vollmar, Principal Scientist and Group Leader, Merck and Co, Nikhil Jain, Senior Scientist, Insitro, Jeffrey Way, Director of Structural Biology, Harvard Medical School, Ilaria Ferlenghi, Associate Director of Research and Senior Scientific Leader, GlaxoSmithKline Vaccines, Xinchao yu, Head of Structural Biology, Gilead Sciences, Jonathan Whicher, Principal Scientist, Novartis AG, Huixian Wu, Head of Structural Biology, Pfizer, Masaya Yamaguchi, Principal Scientist, Pfizer, Christine Carbone, Structural Biology Scientist, Relay Therapeutics, Jason Yano, Director and Head of Structural Biology, Revolution Medicines, Ryan Casner, Structural Biology and Computational Design Scientist, Sanofi, Steffen Bernard, Associate Director and Structural Biology Lead, Vividion Therapeutics, Yao Fan, Director of Protein Design and Optimization, Tectonic Therapeutic, Kasia Handing, Associate Director, Tango Therapeutics, Ann Boriack-Sjodin, Executive Director and Global Head of Structural Biology, Takeda Pharmaceutical, Madhu Sevvana, Principal Scientist in Structural Biology and Protein Design, Integration Lead, Sanofi